Talha Munir

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig et al. · The Lancet Oncology · 2016 · 796 citations · Full text

Medicine, Hematology, Immunology +7

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak et al. · The Lancet · 2020 · 612 citations · Full text

Medicine, Hematology, Pharmacology +10

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna et al. · Blood · 2020 · 318 citations · Full text

Pharmacy, Health Sciences, Internal Medicine +3

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig et al. · Journal of Clinical Oncology · 2018 · 313 citations · Full text

Medicine, Hematology, Pharmacology +16

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia

Régis Peffault de Latour, Austin Kulasekararaj, Simona Iacobelli et al. · New England Journal of Medicine · 2022 · 298 citations · Full text

Medicine, Hematology, Pharmacotherapy +16